INTRODUCTION
Despite recent case reports of bilirubin encephalopathy in African American glucose-6-phosphate dehydrogenase (G6PD)-deficient neonates, 1, 2 there is a misconception that, in North America, G6PD deficiency need not be considered in the differential diagnosis of hyperbilirubinemia. 3, 4 As G6PD deficiency is an X-linked condition, 5 this misconception has been further entrenched in the management of female neonates, because homozygous deficiency is less frequently encountered than the hemizygous state in males. Furthermore, the heterozygous state, unique to females, was believed for many years to be a benign condition. 6 However, it has recently been shown in Sephardic Jewish neonates with the G6PD Mediterranean mutation that heterozygotes are also at high risk for hyperbilirubinemia. In addition, acute hemolysis with severe hyperbilirubinemia may occur in this genotype. 7, 8 To our knowledge, there are no published reports to date that describe a case of hemolysis and hyperbilirubinemia in an African American female neonate who has molecular confirmation of heterozygous G6PD deficiency.
CASE REPORT
Baby girl J was born at 40 weeks' gestation to a 22-year-old gravida 1, para 1, blood group O Rh positive, African American woman. Delivery was spontaneous, vaginal, without instrumentation. Birth weight was 3645 g. Initial physical examination was normal; the baby was alert, with good color. She breast-fed well.
At age 27 hours, the mother requested that she and the baby be discharged home. In accordance with nursery routine, a predischarge transcutaneous bilirubin screening test was performed with the BiliChek device (Respironics, Marietta, GA). The result was 14.8 mg/ dl, greater than the 95th percentile for hour of life on the nomogram of bilirubin level for hour of age. 9 Serum total bilirubin (STB) value was 14.6 mg/dl. Because the etiology of the hyperbilirubinemia was unclear, a complete blood count (CBC) was performed: this revealed hemoglobin 20.8 g/dl, MCV 107, 3 reticulocyte count 8%; blood smear for red cell morphology was within normal limits for a newborn. The blood group of the baby was O, Rh positive, direct Coombs' test negative. The G6PD enzyme activity level, drawn at the same time as the CBC, was 9.8 U/g Hb, at the lower end of the adult normal range (8.6 to18.6 U/g Hb). As the patient was female, this result was suggestive of a heterozygous G6PD-deficient state. Phototherapy was initiated at 28 hours. At 34 1 / 2 hours, STB value had increased to 17.8 mg/dl, with a direct component of 0.4 mg/dl. At 42 1 / 2 hours, it had decreased to 14.3 mg/dl. Phototherapy was discontinued on the fourth day of life and the infant was discharged with an STB value of 10.6 mg/dl. Neurological examination was normal.
Special Investigations
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the early detection of increased bilirubin production using the CO-Stat End Tidal Breath Analyzer (Natus Medical, San Carlos, CA). She had been tested at 8 and 25 hours of life; however, the results were unknown to the clinical caregivers according to the study design. ETCOc values were 3.1 and 2.5 parts per million (ppm) or l/l, respectively, indicative of considerable hemolysis. For reference, the 95th percentile levels for ETCOc in the study population at the 12±6-and 24±6-hour determinations were 3.2 and 2.5 ppm, respectively, whereas the respective mean values ( ±SD) were 2.1±0.67 and 1.7±0.51. 10 DNA was prepared from peripheral leukocytes. G6PD genotype and uridine diphosphate glucuronosyltransferase 1A1 (UGT) promoter genotype were determined by direct sequencing. The infant was heterozygous for G6PD deficiency (A+ /AÀ, the African variant) and homozygous for the variant promoter [(TA) 7 TAA] of the gene encoding UGT 1A1, as seen in Gilbert's syndrome.
DISCUSSION
The unique aspects of the present case are that not only have coexisting G6PD deficiency in the heterozygous state, and Gilbert's disease, been documented in a hyperbilirubinemic African American female neonate, but considerable hemolysis, predictive of the subsequent icterus, was documented by elevated end-tidal carbon monoxide values at two time periods within the first 25 hours of life. According to the study design, the clinicians taking care of the infant were not aware of the ETCOc results; however, availability of the ETCOc results at an earlier stage may have facilitated recognition of the high-risk status of this neonate for developing hyperbilirubinemia.
In the future, early ETCOc measurement may prove to be a useful technique for the identification of hemolysis in newborns before jaundice is apparent. The neonate had not been recognized to be jaundiced perhaps because of her dark skin pigmentation but, according to routine nursery practice, when the mother requested early discharge, evaluation for hyperbilirubinemia was performed.
Severe hemolysis is a major complication of G6PD deficiency in Africa.
11 Kaplan and Hammerman 12 have recently drawn the attention of pediatricians to the potential dangers of hyperbilirubinemia in G6PD-deficient African American neonates in North America. In addition, in an informal kernicterus registry, Johnson and Brown 13 reported 18 of 80 (22.5%) affected neonates to have G6PD deficiency. Whereas the mere presence of G6PD deficiency does not necessarily imply that this was the only or primary cause of the hyperbilirubinemia, there does seem to be an association between this condition and these recent reports of kernicterus.
The role of hemolysis in the pathogenesis of hyperbilirubinemia in G6PD-deficient neonates appears inconsistent between population groups. Deficiency of bilirubin conjugation, due to coinheritance of the variant promoter of the gene encoding UGT 1A1, as seen in Gilbert's syndrome, appears to be a crucial factor in the pathogenesis of hyperbilirubinemia in G6PD-deficient neonates. 14 -16 A large prospective study would be necessary to determine not only the incidence of neonatal hyperbilirubinemia in the North American G6PD-deficient African American population, but also whether screening with ETCOc would be instrumental in identifying those who are at high risk for hyperbilirubinemia. Meanwhile, bilirubin screening in African American neonates, a high-risk group for G6PD deficiency, before hospital discharge or earlier as clinically indicated, may be prudent in identifying infants at risk for developing severe hyperbilirubinemia. 9, 17 This case report serves once again to bring the relationship between G6PD deficiency and severe hyperbilirubinemia to the fore and should serve as a reminder for pediatricians to consider this condition in their differential diagnosis of unexplained hyperbilirubinemia or hemolysis in African American infants.
